Novartis (NOVN) PT Set at CHF 87 by Kepler Capital Markets

Kepler Capital Markets set a CHF 87 target price on Novartis (VTX:NOVN) in a report published on Tuesday morning, Borsen Zeitung reports. The firm currently has a buy rating on the stock.

A number of other research analysts have also recently commented on NOVN. Jefferies Financial Group set a CHF 95 price target on shares of Novartis and gave the stock a buy rating in a report on Thursday, May 16th. Credit Suisse Group set a CHF 84 price target on shares of Novartis and gave the stock a neutral rating in a report on Friday, May 17th. Morgan Stanley set a CHF 80 price target on shares of Novartis and gave the stock a sell rating in a report on Wednesday, April 10th. JPMorgan Chase & Co. set a CHF 78 price target on shares of Novartis and gave the stock a sell rating in a report on Monday, May 6th. Finally, Deutsche Bank set a CHF 85 price target on shares of Novartis and gave the stock a neutral rating in a report on Tuesday, May 7th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of CHF 88.41.

Novartis has a 1-year low of CHF 72.45 and a 1-year high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Recommended Story: What is Elliott Wave theory?

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.